PF 6743649Alternative Names: PF-06743649; PF6743649
Latest Information Update: 12 Mar 2015
At a glance
- Originator Pfizer
- Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gout
Most Recent Events
- 10 Feb 2015 Pfizer terminates enrolment in phase I trial in Healthy elderly volunteers in USA (NCT02170012)
- 01 Dec 2014 Pfizer completes a phase I trial in Healthy volunteers in USA (NCT02151617)
- 10 Nov 2014 Pfizer terminates a phase I trial in Gout in USA (NCT02187029)